Cantor Fitzgerald set a $29.00 price target on Spring Bank Pharmaceuticals (NASDAQ:SBPH) in a research note issued to investors on Thursday, November 16th. The brokerage currently has a buy rating on the stock.
Several other research analysts also recently commented on the stock. B. Riley assumed coverage on shares of Spring Bank Pharmaceuticals in a report on Monday, November 6th. They set a buy rating and a $30.00 price objective for the company. Chardan Capital lowered their price target on shares of Spring Bank Pharmaceuticals from $34.00 to $30.00 and set a buy rating for the company in a report on Tuesday, August 1st. ValuEngine downgraded shares of Spring Bank Pharmaceuticals from a hold rating to a sell rating in a report on Thursday, August 24th. Finally, Dawson James reaffirmed a buy rating on shares of Spring Bank Pharmaceuticals in a report on Monday, August 7th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The stock has a consensus rating of Buy and a consensus target price of $27.25.
Spring Bank Pharmaceuticals (NASDAQ SBPH) traded up $0.23 on Thursday, hitting $13.73. 33,646 shares of the company’s stock traded hands, compared to its average volume of 34,085. Spring Bank Pharmaceuticals has a twelve month low of $6.31 and a twelve month high of $18.93.
A number of institutional investors have recently bought and sold shares of SBPH. DAFNA Capital Management LLC purchased a new stake in Spring Bank Pharmaceuticals in the 2nd quarter worth about $217,000. C WorldWide Group Holding A S purchased a new position in shares of Spring Bank Pharmaceuticals during the second quarter worth approximately $340,000. EAM Investors LLC purchased a new position in shares of Spring Bank Pharmaceuticals during the second quarter worth approximately $578,000. Vanguard Group Inc. purchased a new position in shares of Spring Bank Pharmaceuticals during the second quarter worth approximately $794,000. Finally, Morse Asset Management Inc increased its position in shares of Spring Bank Pharmaceuticals by 156.9% during the second quarter. Morse Asset Management Inc now owns 63,700 shares of the company’s stock worth $862,000 after acquiring an additional 38,900 shares during the period. 29.70% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Cantor Fitzgerald Analysts Give Spring Bank Pharmaceuticals (SBPH) a $29.00 Price Target” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2017/12/05/cantor-fitzgerald-analysts-give-spring-bank-pharmaceuticals-inc-sbph-a-29-00-price-target.html.
Spring Bank Pharmaceuticals Company Profile
Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.
Receive News & Ratings for Spring Bank Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.